Cytokine status indicators in children with acute respiratory viral infections after treatment with intranasal interferon-based medicine

O I Afanasyeva,E A Dondurey,V S Timonina,E V Obraztsova,V V Gonchar,A S Simbirtsev,L V Osidak,E G Golovacheva,E S Goncharova,D A Lioznov

doi:10.22627/2072-8107-2021-20-4-6-12

Abstract

Objective: to study the dynamics of local and systemic cytokine production in children with different clinical forms of acute respiratory viral infections (ARVI), including COVID-19, and to assess the effectiveness of local interferon-based therapy.Patients and methods: The study included 180 patients aged from 1 month to 17 years with сonfirmed acute respiratory viral infections (ARVI), including COVID-19. Patients were divided into 2 groups (main and control) of 90 people each. In the main group patients received the intranasal interferon-based medicine Grippferon® in addition to the basic therapy, the control group patients received only basic therapy. The cytokine status was assessed by the content of IFN-α and -γ, IL-1β, IL-8, IL-4, IL-10, IL-17 in blood serum and in nasopharyngeal secretions by enzyme immunoassay kits ("Cytokine", St. Petersburg).Results: Statistically significant differences were revealed in the systemic and local content of individual cytokines in ARVI of different etiologies, depending on the level of damage to the respiratory tract. The use of the interferon-based medicine Grippferon® for intranasal use in children in the early stages of ARVI, including COVID-19, helps to decrease the high content of cytokines IL-1β and IL-8 in the nasopharynx by reducing the viral load. As a result, the duration of catarrhal disease symptoms and intoxication was also significantly reduced as well as the pathogen elimination time.

Highlights

Cytokine status indicators in children with acute respiratory viral infections after treatment with intranasal interferon-based medicine
Patients and methods: The study included 180 patients aged from 1 month to 17 years with сonfirmed acute respiratory viral infections (ARVI), including COVID-19
The cytokine status was assessed by the content of IFN-α and -γ, IL-1β, IL-8, IL-4, IL-10, IL-17 in blood serum and in nasopharyngeal secretions by enzyme immunoassay kits

Summary

ОРИГИНАЛЬНЫЕ СТАТЬИ

Интраназальное применение препарата рекомбинантного IFN-α2b (Гриппферона) у детей в ранние сроки ОРВИ, в том числе при COVID-19, способствовало снижению высокого содержания цитокинов IL-1β и IL-8 в носоглотке за счет уменьшения вирусной нагрузки на организм, что приводило к сокращению продолжительности катаральных симптомов заболевания и интоксикации. For citation: Afanasyeva O.I., E.G. Golovacheva, L.V. Osidak, V.S. Timonina, V.V. Gonchar, E.V. O braztsova, E.A. Dondurey, E.S. Goncharova, A.S. Simbirtsev, D.A. Lioznov. Показатели цитокинового статуса у детей с ОРВИ на фоне терапии интраназальными препаратами интерферона http://orcid.org/0000-0001-8762-6724 Гончарова Е.С. Исследованиями было доказано, что у пациентов с тяжелыми формами гриппа и ОРВИ различной этиологии, включая COVID-19, число плазмоцитоидных дендритных клеток снижается и отмечается угнетение ИФН-ответа в сочетании с повышением активности провоспалительных реакций, что способствует генерализации инфекции [8, 9].

Материалы и методы исследования

Результаты и их обсуждение

Findings

Наблюдаемые группы детей Children groups